COMMUNIQUÉ DE PRESSE publié le 15/07/2024 à 08:15, il y a 1 année 8 mois Nyxoah Appoints Scott Holstine as Chief Commercial Officer Nyxoah appoints Scott Holstine as Chief Commercial Officer, bringing 26 years of medical device industry experience. His role is crucial for Nyxoah's U.S. launch success in treating Obstructive Sleep Apnea Chief Commercial Officer Medical Technology Nyxoah Obstructive Sleep Apnea Scott Holstine
BRÈVE publiée le 03/07/2024 à 12:35, il y a 1 année 8 mois Nyxoah signe un accord de prêt de 37,5 millions d'euros avec la Banque européenne d'investissement Technologie Médicale Accord De Prêt Banque Européenne D'investissement Nyxoah Apnée Obstructive Du Sommeil
BRÈVE publiée le 03/07/2024 à 12:35, il y a 1 année 8 mois Nyxoah Signs €37.5 Million Loan Agreement with European Investment Bank Loan Agreement Medical Technology European Investment Bank Nyxoah Obstructive Sleep Apnea
COMMUNIQUÉ DE PRESSE publié le 03/07/2024 à 12:30, il y a 1 année 8 mois Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Nyxoah signs a €37.5 million loan facility agreement with the European Investment Bank to boost research, development, and manufacturing capacity for sleep apnea solutions Research And Development European Investment Bank Sleep Apnea Nyxoah €37.5 Million Loan
Publié le 23/03/2026 à 08:10, il y a 7 heures 18 minutes Entrée en négociations exclusives de cession de la participation dans Winncare
Publié le 20/03/2026 à 19:00, il y a 2 jours 20 heures AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Publié le 20/03/2026 à 19:00, il y a 2 jours 20 heures AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Publié le 20/03/2026 à 18:15, il y a 2 jours 21 heures Publication of AXA’s 2025 Universal Registration Document
Publié le 20/03/2026 à 18:15, il y a 2 jours 21 heures Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Publié le 23/03/2026 à 14:05, il y a 1 heure 23 minutes Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Publié le 23/03/2026 à 14:00, il y a 1 heure 28 minutes BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Publié le 23/03/2026 à 13:05, il y a 2 heures 23 minutes SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Publié le 23/03/2026 à 12:32, il y a 2 heures 56 minutes Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Publié le 23/03/2026 à 12:30, il y a 2 heures 58 minutes Digi Power X to Announce 2025 Year End Financial Results on March 31st
Publié le 23/03/2026 à 15:05, il y a 23 minutes Heidrick & Struggles Launches Heidrick Immersive, an AI-Enhanced Platform for Observing Leadership in Motion
Publié le 23/03/2026 à 14:30, il y a 58 minutes Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Publié le 23/03/2026 à 14:30, il y a 58 minutes Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Publié le 23/03/2026 à 14:24, il y a 1 heure 4 minutes Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
